These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 9723819)

  • 1. Population pharmacokinetics of ondansetron: a covariate analysis.
    de Alwis DP; Aarons L; Palmer JL
    Br J Clin Pharmacol; 1998 Aug; 46(2):117-25. PubMed ID: 9723819
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population pharmacokinetics of doxorubicin: establishment of a NONMEM model for adults and children older than 3 years.
    Kontny NE; Würthwein G; Joachim B; Boddy AV; Krischke M; Fuhr U; Thompson PA; Jörger M; Schellens JH; Hempel G
    Cancer Chemother Pharmacol; 2013 Mar; 71(3):749-63. PubMed ID: 23314734
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population pharmacokinetics of intravenous ondansetron in oncology and surgical patients aged 1-48 months.
    Mondick JT; Johnson BM; Haberer LJ; Sale ME; Adamson PC; Coté CJ; Croop JM; Russo MW; Barrett JS; Hoke JF
    Eur J Clin Pharmacol; 2010 Jan; 66(1):77-86. PubMed ID: 19798490
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic modeling and Monte Carlo simulation of ondansetron following oral administration in dogs.
    Baek IH; Lee BY; Kang J; Kwon KI
    J Vet Pharmacol Ther; 2015 Apr; 38(2):199-202. PubMed ID: 25131428
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and bioequivalence testing of generic ondansetron preparations in healthy Thai male volunteers.
    Rojanasthien N; Manorot M; Kumsorn B
    Int J Clin Pharmacol Ther; 1999 Nov; 37(11):548-54. PubMed ID: 10584976
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Memantine pharmacotherapy: a naturalistic study using a population pharmacokinetic approach.
    Kornhuber J; Kennepohl EM; Bleich S; Wiltfang J; Kraus T; Reulbach U; Meineke I
    Clin Pharmacokinet; 2007; 46(7):599-612. PubMed ID: 17596105
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Automated covariate model building within NONMEM.
    Jonsson EN; Karlsson MO
    Pharm Res; 1998 Sep; 15(9):1463-8. PubMed ID: 9755901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of clinical irrelevance criteria in covariate model building with application to dofetilide pharmacokinetic data.
    Tunblad K; Lindbom L; McFadyen L; Jonsson EN; Marshall S; Karlsson MO
    J Pharmacokinet Pharmacodyn; 2008 Oct; 35(5):503-26. PubMed ID: 19011957
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population pharmacokinetics of raltitrexed in patients with advanced solid tumours.
    Blair EY; Rivory LP; Clarke SJ; McLachlan AJ
    Br J Clin Pharmacol; 2004 Apr; 57(4):416-26. PubMed ID: 15025739
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of target controlled infusion to derive age and gender covariates for propofol clearance.
    White M; Kenny GN; Schraag S
    Clin Pharmacokinet; 2008; 47(2):119-27. PubMed ID: 18193918
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bioequivalence study of ondansetron tablet in healthy Thai male volunteers.
    Lohitnavy M; Chaijittiprasert K; Polnok S; Lohitnavy O; Taytiwat P
    J Med Assoc Thai; 2002 Jul; 85(7):808-13. PubMed ID: 12296413
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population pharmacokinetics of APOMINE: a meta-analysis in cancer patients and healthy males.
    Bonate PL; Floret S; Bentzen C
    Br J Clin Pharmacol; 2004 Aug; 58(2):142-55. PubMed ID: 15255796
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ondansetron metabolism and pharmacokinetics.
    Pritchard JF
    Semin Oncol; 1992 Aug; 19(4 Suppl 10):9-15. PubMed ID: 1387254
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patient characteristics influencing ciclosporin pharmacokinetics and accurate Bayesian estimation of ciclosporin exposure in heart, lung and kidney transplant patients.
    Saint-Marcoux F; Marquet P; Jacqz-Aigrain E; Bernard N; Thiry P; Le Meur Y; Rousseau A
    Clin Pharmacokinet; 2006; 45(9):905-22. PubMed ID: 16928152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population pharmacokinetics of melphalan in paediatric blood or marrow transplant recipients.
    Nath CE; Shaw PJ; Montgomery K; Earl JW
    Br J Clin Pharmacol; 2007 Aug; 64(2):151-64. PubMed ID: 17324241
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population pharmacokinetic investigation of actinomycin-D in children and young adults.
    Mondick JT; Gibiansky L; Gastonguay MR; Skolnik JM; Cole M; Veal GJ; Boddy AV; Adamson PC; Barrett JS
    J Clin Pharmacol; 2008 Jan; 48(1):35-42. PubMed ID: 18094218
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A population pharmacokinetic model of valproic acid in pediatric patients with epilepsy: a non-linear pharmacokinetic model based on protein-binding saturation.
    Ding J; Wang Y; Lin W; Wang C; Zhao L; Li X; Zhao Z; Miao L; Jiao Z
    Clin Pharmacokinet; 2015 Mar; 54(3):305-17. PubMed ID: 25388986
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population pharmacokinetics of cilengitide in adult and pediatric cancer patients from a nonlinear mixed-effects analysis.
    Zühlsdorf M; Bhattaram VA; Campioni M; Krösser S; Derendorf H; Kovar A
    J Clin Pharmacol; 2014 Dec; 54(12):1391-9. PubMed ID: 24911832
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stability and performance of a population pharmacokinetic model.
    Ette EI
    J Clin Pharmacol; 1997 Jun; 37(6):486-95. PubMed ID: 9208355
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of two population pharmacokinetic programs, NONMEM and P-PHARM, for tacrolimus.
    Staatz CE; Tett SE
    Eur J Clin Pharmacol; 2002 Dec; 58(9):597-605. PubMed ID: 12483452
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.